JNJ, LLY, PFE: The Hype Around GLP-1 Drugs

Johnson & Johnson (JNJ) delivered a strong quarter and tight expense control was evident as SG&A and R&D both grew below expectations, notes Lee Brown. He discusses health care trends to watch and names in the health care sector to watch including JNJ, LLY, NVO, and PFE. He talks about how JNJ’s innovative medicines segment delivered a strong performance primarily driven by its immunology franchise. He examines the hype around GLP-1 drugs and Daiichi Sankyo and Merck’s $22B commercialization deal. Tune in to find out more about the stock market today.

The Watch List

20 Oct 2023

SHARE

Schwab Network's Newsletters

Daily insights for every investor

ON AIR
8:00 pm
Market Overtime
replay
12:00 am
The Wrap
REPLAY
12:30 am
Market On Close
REPLAY
2:00 am
Trading 360
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Opening Bell With Nicole Petallides
9:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
7:30 pm
Market Overtime
REPLAY
ON AIR
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market On Close
REPLAY
10:00 pm
Trading 360
REPLAY
11:00 pm
The Wrap
REPLAY